My 3 Favorite Hotel REITs Plus A Las Vegas Wild Card
Source: seekingalpha.com

Ryman Hospitality is rated BUY, with a projected 12-month total return of more than 20%, supported by its group-focused convention-resort moat and valuation below historical multiples. Host Hotels is rated HOLD despite trophy assets, an investment-grade balance sheet and disciplined capital allocation because its valuation is viewed as full. Apple Hospitality is also rated HOLD, offering a 6.2% monthly yield, conservative leverage and a diversified rooms-focused portfolio for income investors.
Analysis
RHP’s differentiated exposure is less about lodging beta and more about captive group demand: convention calendars are booked well in advance, creating greater revenue visibility and reducing OTA dependence relative to room-centric peers. If corporate travel budgets remain stable, incremental group revenue should convert at high flow-through because food, beverage, and ancillary spend leverage a largely fixed property cost base. The key 1-3 month catalyst is evidence of sustained forward bookings and pricing at its major properties; the 6-18 month upside requires convention demand to remain resilient through a slower corporate spending environment.
HST is the cleaner balance-sheet optionality vehicle, but that optionality is unlikely to be monetized without a dislocation in hotel real-estate values or a meaningful asset-recycling program. Trophy urban and resort assets carry higher sensitivity to affluent leisure and international demand, so a weakening consumer or stronger dollar could produce RevPAR underperformance and multiple compression despite lower financing risk. Conversely, a downturn that forces private hotel owners to sell would favor HST’s acquisition capacity and could justify owning it as a late-cycle consolidator rather than for near-term operating upside.
APLE’s distribution appeal masks the relevant risk: its dividend is supported by highly diversified but economically sensitive select-service cash flows, where modest occupancy declines can have outsized FFO coverage consequences after fixed property costs. A soft-landing environment supports stable income, but the equity is unlikely to rerate materially unless management demonstrates per-share growth through accretive capital allocation rather than simply maintaining the payout. The contrarian view is that investors may be overpaying for headline yield if Treasury yields remain elevated; income capital can rotate quickly when the spread versus risk-free alternatives narrows.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
Key Decisions for Investors
- Initiate a 6-12 month pair trade: long RHP / short HST in equal dollar amounts. The thesis is relative EBITDA and RevPAR resilience from group-convention demand versus premium-lodging cyclicality; target 15-20% relative return. Exit if RHP’s forward group bookings weaken materially or HST announces a clearly accretive large-scale acquisition/asset-sale catalyst.
- Use RHP weakness around macro or travel-demand scares to build exposure rather than chase strength. Require confirmation from quarterly forward-booking commentary, group ADR, and adjusted FFO guidance; a reduction in full-year FFO guidance or convention cancellation trend would falsify the long case.
- Maintain APLE only as an income allocation, not a total-return growth position, with a 6-18 month horizon. Monitor dividend/FFO coverage, same-store RevPAR, and net debt-to-EBITDA; reduce if payout coverage deteriorates or management funds the dividend through incremental leverage.
- Keep HST on a watch list for a hotel-property market dislocation rather than initiating at a full valuation. A sharper-than-expected recession, private-market cap-rate reset, or asset acquisition pipeline could create an entry point where its balance sheet becomes an earnings-growth advantage.
More News
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- ‘There’s nothing temporary about a temporary store’: How Spirit Halloween’s CEO took it from 130 stores to 1,550—and swallowed your mall’s Hot Topic